The presence of certain genetic factors in some patients protects them from developing coronary artery disease (CAD). This study seeks to identify these protective genetic factors and to expand our understanding of the genetic contribution to the development of CAD.

The aim of the current study is to evaluate the effects of ziltivekimab on heart failure symptoms and physical function in participants with mildly reduced or preserved heart function and evidence of inflammation.

The purpose of this study is to understand how body fat and skeletal muscle in your body impacts your heart, kidney, and metabolic health. This research may help to better diagnose and treat patients and prevent progression of cardiovascular-kidney-metabolic diseases.

To demonstrate safety and efficacy of the Cordella PA Sensor System in both NYHA Class II and Class III heart failure patients.

To evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of advanced heart failure patients who are not dependent on intravenous inotrope.

This study is meant to help identify patients who are at high risk for cardiovascular events.

The purpose of this study is to test the effectiveness of Vertex Pulmonary Embolectomy System in treating pulmonary embolisms

There are multiple devices that have been developed and approved to help treat heart failure symptoms, yet some patients who qualify for these devices are denied authorization by their insurance. We look to describe trends across the United States.

This study is meant to test how effective the Laguna system is at treating pulmonary embolism.

A Phase IV, multicenter, randomized, open label trial to evaluate the effectiveness of inclisiran + usual care vs usual care alone as a tool to close care gaps within a pragmatic framework in an inclusive and underrepresented population at high risk for or diagnosed with ASCVD.